Treatment and prognosis of type B2 thymoma

World Journal of Surgical Oncology

Research

Zhengbo Song¹  Xiangyu Jin¹  Yiping Zhang¹ 

[1] Department of Chemotherapy, Zhejiang Cancer Hospital, 38 Guangji Road, 310022, Hangzhou, China;Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology, 310022, Hangzhou, Zhejiang Province, China;

关键词: thymoma;    type B2;    treatment;    prognosis;   

DOI  :  10.1186/1477-7819-12-291

 received in 2014-02-06, accepted in 2014-09-02,  发布年份 2014

来源: Springer

【 摘 要 】

BackgroundBecause of the rarity of thymoma, no randomized trials have prospectively detected the prognosis and optimal treatment for type B2 thymoma. The aim of this study is to investigate the treatment and prognosis for patients with type B2 thymoma.MethodsWe retrospectively evaluated the outcome of 42 patients with type B2 thymoma who were treated between 1995 and 2010 in Zhejiang Cancer Hospital. Survival curves were plotted using the Kaplan–Meier method. The Cox proportional hazard model was used for multivariate analysis.ResultsThe current study included 42 patients. The 5-year disease-free survival and overall survival rates were 62.8% and 84.9%, respectively. There were significant differences in disease-free survival and overall survival among different Masaoka stages (both P < 0.001). Univariate and multivariate analysis revealed that Masaoka stage was associated with disease-free survival and overall survival (P = 0.00 and 0.001, respectively).ConclusionsOur results indicate that Masaoka stage affects disease-free survival and overall survival of patients with type B2 thymoma.

【 授权许可】

Unknown   
© Song et al.; licensee BioMed Central Ltd. 2014. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.